Evidence map›Paper›PMID 33040189›Full record

ArticleJournal of cancer research and clinical oncology2021

An online tool for predicting the prognosis of cancer patients with SARS-CoV-2 infection: a multi-center study.

Congkuan Song, Zhe Dong, Hongyun Gong, Xiao-Ping Liu, Xiaorong Dong, Aifen Wang, Yuan Chen, Qibin Song, Weidong Hu

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Applying the digital data and the bioinformatics tools in SARS-CoV-2 research.Computational and structural biotechnology journal · 2023
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Congkuan Song *Department of Thoracic Surgery, ZhongNan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, Hubei, China.
Zhe Dong *Department of Thoracic Surgery, ZhongNan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, Hubei, China.
Hongyun Gong *Cancer Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China.
Xiao-Ping LiuDepartment of Urology, ZhongNan Hospital of Wuhan University, Wuhan, China.
Xiaorong DongDepartment of Thoracic Oncology, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Aifen WangDepartment of Obstetrics and Gynecology, Zhangjiagang Hospital TCM, Nanjing University of Chinese Medicine, Nanjing, China.
Yuan ChenDepartment of Thoracic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430000, Hubei, China. chenyuan008@163.com.
Qibin SongCancer Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China. qibinsong@whu.edu.cn.
Weidong HuDepartment of Thoracic Surgery, ZhongNan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, Hubei, China. huwd@whu.edu.cn.ORCID http://orcid.org/0000-0003-3646-8572
Wuhan University · CNHuazhong University of Science and Technology · CNNanjing University of Chinese Medicine · CNTongji Hospital · CN

Funding

Zhongnan Hospital of Wuhan University Science Technology and Innovation Cultivating Fund cxpy2017041
6 · The paper itself

Abstract

purposeDuring the 2019 coronavirus disease (COVID-19) pandemic, oncologists face new challenges, and they need to adjust their cancer management strategies as soon as possible to reduce the risk of SARS-CoV-2 infection and tumor recurrence. However, data on cancer patients with SARS-CoV-2 infection remains scarce.

methodsWe conducted a retrospective study on 223 cancer patients with SARS-CoV-2 from 26 hospitals in Hubei, China. An individualized nomogram was constructed based on multivariate Cox analysis. Considering the convenience of the nomogram application, an online tool was also created. The predictive performance and clinical application of nomogram were verified by C-index, calibration curve and decision curve analysis (DCA).

resultsAmong cancer patients with SARS-CoV-2, there were significant differences in clinical characteristics between survivors and non-survivors, and compared with patients with solid tumors including lung cancer, patients with hematological malignancies had a worse prognosis. Male, dyspnea, elevated PCT, increased heart rate, elevated D-dimers, and decreased platelets were risk factors for these patients. Furthermore, a good prediction performance of the online tool (dynamic nomogram: https://covid-19-prediction-tool.shinyapps.io/DynNomapp/ ) was also fully demonstrated with the C-indexes of 0.841 (95% CI 0.782-0.900) in the development cohort and 0.780 (95% CI 0.678-0.882) in the validation cohort.

conclusionOverall, cancer patients with SARS-CoV-2 had unique clinical features, and the established online tool could guide clinicians to predict the prognosis of patients during the COVID-19 epidemic and to develop more rational treatment strategies for cancer patients.

Indexed as

AgedChinaCOVID-19FemaleHumansMaleMiddle AgedNeoplasmsNomogramsPrognosisRetrospective StudiesSARS-CoV-2CancerCOVID-19NomogramPrognosisSARS-CoV-2

Identifiers

PMID33040189
PMCPMC7548053
OpenAlexW3092275814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.